Patients with the following are excluded:
- Prior history of a malignancy other than cutaneous basal cell or cervical carcinomas.
- Other significant, chronic underlying medical illness which would impair study completion.
- Liver dysfunction as demonstrated by lab results.
- Laboratory evidence of compromised bone marrow function.
- Any other experimental agents.
- Any probenecid-containing product.
Patients are excluded if they have a history of symptoms characteristic of CDC class I or IV including any of the following:
- Unintentional weight loss of greater than 10 lbs, or more than 10 percent of usual body weight within the last 16 weeks.
- Unexplained fever > 38.5 degrees C on more than 14 consecutive days or on more than 15 days in the previous 30-day period.
- Unexplained diarrhea defined by = or > 2 liquid stools per day persisting for = or > 14 days or 15 days in any 30-day period.
- OR History of secondary infections associated with AIDS related complex (ARC) including:
- Recurrent oral candidiasis documented by morphology or by response to antifungal therapy within 3 years.
- Herpes zoster infection within 3 years.
- Oral hairy leukoplakia at any time.
- OR History of opportunistic disease fulfilling the CDC surveillance definition of AIDS.
- Signs and symptoms at baseline characteristic of acute HIV disease (CDC group I).
- Evidence of significant neurologic dysfunction as currently defined by CDC following standard neurologic screening and AIDS Dementia Assessment.
- Previous treatment for greater than 3 months duration with any antiretroviral compound such as zidovudine (AZT).
Excluded within 4 weeks of study entry:
- Treatment with any potentially myelosuppressive drug, nephrotoxic agent, or other experimental therapy.
Excluded within 3 months of study entry:
- Antiretroviral drugs or biologic response modifiers.
Excluded within 4 months of study entry:
- Systemic corticosteroids.
Patients must meet the following criteria:
- HIV infection demonstrated by ELISA and confirmed by Western blot.
- Signs and symptoms of HIV disease limited to those characteristic of CDC groups II (asymptomatic) and III (persistent generalized lymphadenopathy - PGL).
- Ability to give informed consent.
- Willingness to be followed by the originating medical center for the entire 3-year duration of the study.
Active drug or alcohol abuse sufficient in the investigator's opinion to prevent compliance with the study regimen.